# Arcturus Therapeutics Partners with Thermo Fisher for Phase 3 mRNA Cystic Fibrosis Program

> partnership · REPORTED · 2026-07-01

Arcturus Therapeutics announced a strategic collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialization of ARCT-032, its investigational mRNA therapy for cystic fibrosis. The partnership leverages Thermo Fisher's manufacturing and supply chain infrastructure for large-scale clinical and commercial production.

About Arcturus Therapeutics: Arcturus Therapeutics is an mRNA medicines company developing liver and respiratory rare disease therapeutics, with its lead program targeting cystic fibrosis via a novel self-amplifying mRNA approach.

- Company: Arcturus Therapeutics
- Sector: biotech
- Primary source: https://www.businesswire.com/newsroom/industry/health/biotechnology

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.